Results 11 to 20 of about 3,514 (173)

Practical use of sevelamer in chronic kidney disease patients on dialysis in People’s Republic of China

open access: yesTherapeutics and Clinical Risk Management, 2015
Lin Meng,1,2 Bin Fu1 1Department of Nephrology, Second Affiliated Hospital to Tianjin University of Traditional Chinese Medicine, Tianjin, People’s Republic of China; 2Tianjin University of Traditional Chinese Medicine, Tianjin, People’s ...
Meng L, Fu B
doaj   +2 more sources

A Pan-Inhibitor of Phosphate Transporters AP306 in Hemodialysis Patients [PDF]

open access: yesKidney International Reports
Introduction: Hyperphosphatemia in patients undergoing dialysis is not well-controlled. AP306 is a pan-inhibitor of phosphate transporters, designed to block the active uptake of phosphate through the gastrointestinal tract.
Li Wang   +14 more
doaj   +3 more sources

Comparison of efficacy of the phosphate binders nicotinic acid and sevelamer hydrochloride in hemodialysis patients

open access: yesSaudi Journal of Kidney Diseases and Transplantation, 2012
Hyperphosphatemia is a significant risk factor for the development of ectopic calcification and coronary artery diseases in patients on hemodialysis (HD), and must be controlled with the use of phosphate binders.
Farrokhlagha Ahmadi   +3 more
doaj   +2 more sources

Use of sevelamer in chronic kidney disease: beyond phosphorus control

open access: yesNefrología (English Edition), 2015
Sevelamer is a non-calcium phosphate binder used in advanced chronic kidney disease (CKD) and in dialysis for hyperphosphataemia control. Several experimental, observational studies and clinical trials have shown that sevelamer has pleiotropic effects ...
Laura Rodríguez-Osorio   +6 more
doaj   +2 more sources

Clinical and economic aspects of sevelamer therapy in end-stage renal disease patients

open access: yesInternational Journal of Nephrology and Renovascular Disease, 2014
Shahrzad OssarehDepartment of Medicine, Nephrology Section, Hasheminejad Kidney Center, Iran University of Medical Sciences, Tehran, IranAbstract: Phosphate control is still a great challenge in chronic kidney disease (CKD), and in spite of the great ...
Ossareh S
doaj   +1 more source

Uso del sevelamer en la enfermedad renal crónica. Más allá del control del fósforo [PDF]

open access: yesNefrología, 2015
El sevelamer es un captor no cálcico de fósforo que se utiliza en la ERC avanzada y en diálisis para el control de la hiperfosforemia. Varios estudios experimentales, observacionales y ensayos clínicos han mostrado que el sevelamer tiene efectos ...
Laura Rodríguez-Osorio   +6 more
doaj   +2 more sources

Repurposing of sevelamer as a novel antidote against aluminum phosphide poisoning: An in vivo evaluation

open access: yesHeliyon, 2023
Aluminum phosphide (AlP) is widely used for protecting grains from pests. AlP releases toxic phosphine gas (PH3) while exposed to humidity. Poisoning with these tablets is dangerous and can cause death or serious injuries. Up to now, no definite antidote
Reza Heidari   +3 more
doaj   +1 more source

Lower gastrointestinal bleeding in a patient receiving sevelamer: Case report

open access: yesSAGE Open Medical Case Reports, 2021
Phosphate binders such as sevelamer are widely used in patients with chronic kidney disease to lower serum phosphate levels. We present a case of a 67-year-old woman with lower gastrointestinal bleeding after 9 days of using sevelamer carbonate (Renvela ®
Tessa S Schoot   +2 more
doaj   +1 more source

Efficacy and Safety of Sevelamer Carbonate in Chinese Nondialysis Chronic Kidney Disease Patients with Hyperphosphatemia: A Randomized, Double-Blind, Parallel-Group Study

open access: yesKidney Diseases, 2022
Introduction: Previous studies suggested that sevelamer carbonate is well tolerated with a favorable efficacy and safety profile in both dialysis and nondialysis patients in Europe; however, the efficacy remains controversial, and few studies have ...
Wei Chen   +21 more
doaj   +1 more source

Home - About - Disclaimer - Privacy